我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

参慈胶囊影响人肺腺癌A549/DDP裸鼠体内多药耐药DNA损伤修复的研究(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2016年03期
页码:
1-4
栏目:
实验研究
出版日期:
2016-05-15

文章信息/Info

Title:
Study on the Influence of Shenci Capsule on Lung Adenocarcinoma A549/DDPMultidrug Resistance and the Repair of DNA Damage in Nude Mice
作者:
梁昆徐立群△薛兴阳邬晓东于礼建吴迪邹莹
广州医科大学院附属肿瘤医院,广东 广州 510095
Author(s):
LIANG Kun XU Liqun XUE Xingyang WU Xiaodong YU Lijian WU Di ZOU Ying
Cancer Center of Guangzhou Medical University, Guangzhou 510095, China
关键词:
肺癌 参慈胶囊 顺铂耐药 DNA损伤修复
Keywords:
lung cancer Shenci capsule cisplatin resistance DNA damage repair
分类号:
R285.5
DOI:
10.19288/j.cnki.issn.1000-2723.2016.03.001
文献标识码:
A
摘要:
目的探讨参慈胶囊对人肺腺癌A549/DDP裸鼠体内多药耐药的影响。方法将40只C57BL/6小鼠接种人肺腺癌A549/DDP细胞悬液建立实体瘤模型,随机分为参慈胶囊组、参慈胶囊+顺铂组、顺铂组、对照组。对照组予等量生理盐水,其余各组荷瘤小鼠均用药21d,采用FQ-PCR技术检测人肺腺癌A549/DDP肺癌组织ERCC1mRNA、RRM1mRNA、hMLH1mRNA、BRCA1mRNA的表达情况。结果参慈胶囊能够降低ERCC1、RRM1、BRCA1基因的表达,且能够增加hMLH1mRNA基因的表达。结论通过多基因调节以改善人肺腺癌A549/DDP裸鼠体内顺铂耐药状态,可能是参慈胶囊逆转肺癌多药耐药的途径之一。
Abstract:
Objective To explore the influence of Shenci capsule on lung adenocarcinoma A549/DDP multidrug resistance in nude mice. Methods Vaccinate 40 C57BL/6 mice with lung adenocarcinoma A549/DDP cell suspension and establish solid tumor model, randomly dividing into Shenci capsule team, Shenci capsule+cisplatin group, cisplatin group and comparison team. Control groups are given same amount of physiological saline and other groups of tumor-bearing mice offered medication 21d, adopt FQ-PCR technology to examine expressions of lung adenocarcinoma A549/DDP lung cancer tissues ERCC1 mRNA, RRM1mRNA, hMLH1mRNA, BRCA1mRNA. Results The results could reduce the expression of ERCC1, RRM1 and BRCA1 genes, and increase the expression of hMLH1mRNA gene. Conclusion Using multi-gene regulation to improve the cisplatin resistance state of lung adenocarcinoma A549/DDP in nude mice, it may be one of the methods of Shenci capsule reversing lung cancer multidrug resistance.

参考文献/References

[1] 徐立群,徐萌,陈锐深,等. 仙鱼汤配合TP方案治疗Ⅲb及Ⅳ期非小细胞肺癌的近期疗效观察[J]. 新中医,2011,43(10):72-74.
[2] 徐立群,张荣华,薛兴阳,等. 参慈胶囊联合顺铂抑制小鼠Lewis肺癌组织的血管生成机制研究[J]. 中国病理生理学杂志,2010,26(12):2347-2350.
[3] 徐立群,薛兴阳,邬晓东,等. 参慈胶囊联合顺铂对小鼠Lewis肺癌组织survivin、livin表达的影响[J]. 中药材,2013,36(2):294-297.
[4] 吴广洲,沈振亚,刘国峰,等. 三氧化二砷对人肺腺癌细胞A549/DDP裸鼠体内多药耐药逆转作用[J]. 苏州大学学报(医学版),2011,31(1):79-83.
[5] 唐春兰,杨和平,周向东. DNA损伤修复与肺癌顺铂耐药机制的研究进展[J]. 中国肺癌杂志,2012,14(12):960-964.
[6] 杨君,殷东风. 辨证分型防治恶性肿瘤化疗迟发性呕吐研究简况[J]. 实用中医内科杂志,2015,29(10):178-180.
[7] 汤钊猷. 现代肿瘤学[M]. 3版. 上海:复旦大学出版社,2011:1869.
[8] Fadda E. Role of the XPA protein in the NER pathway:a perspective on the function of structural disorder in macromolecular assembly[J]. Comput Struct Biotechnol J,2015,14:78-85.
[9] Manandhar M,Boulware KS,Wood RD. The ERCC1 and ERCC4(XPF)genes and gene products[J]. Gene,2015,569(2):153-161.
[10] Coskunpinar E,Yildiz P,Aynaci E,et al. Investigation of some DNA repair genes association in non small cell lung cancer[J]. Cellular and Molecular Biology(Noisy-le-Grand,France),2015,61(8):57-62.
[11] Mlak R,Krawczyk P,Ciesielka M,et al. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient[J]. Clin Transl Oncol,2015.
[12] Vageli DP,Zaravinos A,Daniil Z,et al. hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma:correlation with patient survival and response to adjuvant chemotherapy treatment[J]. Int J Biol Markers,2013,27(4):e400-404.
[13] 韩婧,李江. DNA 修复相关基因启动子甲基化和肿瘤化疗耐药的进展[J]. 上海交通大学学报(医学版),2011,31(1):95-98.
[14] Aparicio T,Baer R,Gottesman M,et al. MRN,CtIP,and BRCA1 mediate repair of topoisomerase II-DNA adducts[J]. J Cell Biol,2016,212(4):399-408.
[15] Muraoka-Cook RS,Caskey LS,Sandahl MA,et al. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1[J]. Molecular and Cellular Biology,2006,26(17):6412-6424.
[16] De Luca P,De Siervi A. Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis[J]. Frontiers in Bioscience,2016,8:72-83.

备注/Memo

备注/Memo:
* 基金项目: 广州市卫生局中医药科技项目(20132A011035) 收稿日期: 2016 - 04 - 27 作者简介: 梁昆(1979-),男,广东番禺人,主治中医师,研究方向:中西医结合临床肿瘤。△通信作者:徐立群,E-mail:liangkunys@126.com
更新日期/Last Update: 2016-05-20